Eligibility for dapagliflozin and empagliflozin in real-world heart failure based on DAPA-HF, DELIVER, EMPEROR-Reduced and EMPEROR-Preserved selection criteria
Clinical course and related costs of patients with type 2 diabetes and heart failure and/or chronic kidney disease, drawn from a sample of more than 7 million people